Verano Announces Filing of Final Base Shelf Prospectus
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS...
News
GigCapital2 Stockholders Approve Business Combinations with UpHealth Holdings, Inc. and Cloudbreak Health, LLC
PALO ALTO, Calif. & DELRAY BEACH, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--$GIX--GigCapital2, Inc. (“GigCapital2”) (NYSE: GIX, GIX.U, GIX.RT, and GIX.WS) announced...
With Hundreds of Bio Industry Jobs Open and Company Expansions Underway, Companies Are Investing in Industry-Intensive Training and Professional Development
PORTLAND, Ore.--(BUSINESS WIRE)--#BioPro--With large company expansions such as Micro Systems Engineering’s upcoming Lake Oswego-area advanced automated manufacturing expansion, Genentech’s Hillsboro...
Leveljump to Present at GCFF Virtual Healthcare Conference on June 10, 2021
Toronto, Ontario--(Newsfile Corp. - June 4, 2021) - Leveljump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the...
Sanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance its Comprehensive Wound and Skin Care Strategy
FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech...
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase...
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development...
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results...
Y-mAbs Announces Update on Omburtamab for DIPG
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ...
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to...
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell,...
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade...
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th...
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific...
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, June 4, 2021...
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData...
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patientsDURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE)...
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination...
Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per...